The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6283-6291

  Leftheris, Katerina ^a   Ahmed, Gulzar ^a   Chan, Ran ^a   Dyckman, Alaric J ^a   Hussain, Zahid ^a   Ho, Kan ^a   Hynes Jr , John ^a   Letourneau, Jeffrey ^a   Li, Wei ^a   Lin, Shuqun ^a   Metzger, Axel ^a   Moriarty, Kevin J ^a   Riviello, Chris ^a   Shimshock, Yvonne ^a   Wen, James ^a   Wityak, John ^a   Wrobleski, Stephen T ^a   Wu, Hong ^a   Wu, Junjun ^a   Desai, Madhuri ^a   Gillooly, Kathleen M ^a   Lin, Tsung H ^a   Loo, Derek ^a   McIntyre, Kim W ^a   Pitt, Sidney ^a   Shen, Ding Ren ^a   Shuster, David J ^a   Zhang, Rosemary ^a   Diller, David ^a   Doweyko, Arthur ^a   Sack, John ^a   Baldwin, Jack ^a   Barrish, Joel ^a   Dodd, John ^a   Henderson, Ian ^a   Kanner, Steve ^a   Schieven, Gary L ^a   Webb, Maria ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAZEPAN 1 YL TRIAMINOTRIAZINE DERIVATIVE; 4 METHYL 1,4 DIAZEPAN 1 YL TRIAMINOTRIAZINE DERIVATIVE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADENOSINE TRIPHOSPHATE; AMIDE; ASPARTIC ACID; CARBONYL DERIVATIVE; DORAMAPIMOD; ENZYME INHIBITOR; ETANERCEPT; GLUTAMINE; HYDROGEN; INFLIXIMAB; METHIONINE; METHOXYAMINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SYNAPTOPHYSIN; TRIAMINOTRIAZINE ANILINE AMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; RAT; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

ADMINISTRATION, ORAL; AMIDES; ANILINE COMPOUNDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BENZAMIDES; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, INBRED LEW; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9744269944     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049521d     Document Type: Article

References (21)

1. (a) Dinarello, C. A. Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 1991, 3, 941-948.
2. (b) Arend, W. P.; Dayer, J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990, 33, 305-315.
3. (c) Dayer, J. M.; Demczuk, S. Cytokines and other mediators in rheumatoid arthritis. Springer Semin. Immunopathol. 1984, 7, 387-413.
4. (a) Moreland, L. W. Drugs that block tumor necrosis factor: experience in patients with rheumatoid arthritis. Pharmaco-Economics 2004, 22 (2, Suppl.), 39-53.
5. (b) Bresnihan, B. Interleukin-1 receptor antagonist treatment in rheumatoid arthritis. Mod. Ther. Rheum. Dis. 2002, 109-120.
6. (c) Elliott, M. J.; Feldmann, M.; Maini, R. N. TNFα blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. Int. J. Immunopharmacol. 1995, 17 (2), 141-145.
7. (d) Feldmann, M.; Elliott, M. J.; Brennan, F. M.; Maini, R. N. Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis. J. Interferon Res. 1994, 14 (5), 299-300.
8. (a) Cobb, M. H.; Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem. 1995, 270 (25), 14843-14846.
9. (b) Gille, H.; Sharrocks, A. D.; Shaw, P. E. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 1992, 358 (6385), 414-417.
10. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82 (2-3), 389-397.
11. Behr, T. M.; Berova, M.; Doe, C. P.; Ju, H.; Angermann, C.e E.; Boehm, J.; Willette, R. N. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr. Opin. Invest. Drugs (PharmaPress Ltd.) 2003, 4 (9), 1059-1064 and references therein.
12. (a) Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate. J. Med. Chem. 2002, 45 (14), 2994-3008.
13. (b) Branger, J.; Van den Blink, B.; Weijer, S.; Madwed, J.; Bos, C. L.; Gupta, A.; Yong, C.; Polmar, S. H.; Olszyna, D. P.; Hack, C. E.; Van D., Sander J. H.; Peppelenbosch, M. P.; Van der Poll, T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 2002, 168 (8), 4070-4077.
14. (c) Reference 5.
15. (a) Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43 (1), 133-138.
16. (b) Henry, J. R.; Cavender, D. E.; Wadsworth, D. A. p38 Mitogen Activated Protein Kinase as a Target for Drug Discovery. Drugs Future 1999, 24, 1345-1354.
17. (c) Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823. Reference 6a.
18. Moriarty, K.; Shimshock, Y.; Ahmed, G.; Wu, J.; Wen, J.; Li, W.; Erickson, S.; Letourneau, J.; McDonald, E.; Leftheris, K.; Wrobleski, S. T.; Hussain, Z.; Henderson, I.; Metzger, A.; Baldwin, J. J.; Dyckman, A. J. Preparation of s-triazines and pyrimidines for pharmaceutical use as cytokine, especially TNF-α, inhibitors. U.S. Pat. Appl. Publ., 2002, Cont.-in-part US 2002137747 A1.
19. Raingeaud, J.; Whitmarsh, A. J.; Barrett, T.; Derijard, B.; Davis, R. J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 1996, 16 (3), 1247-1255.
20. (a) Fields, R. D.; Lancaster, M. V. Dual attribute continuous monitoring of cell proliferation/cytotoxicity. Am. Biotechnol. Lab. 1993, 11 (4), 48-50.
21. 3-thymidine incorporation assay. J. Immunol. Methods 1994, 170, 211-224.